PharmExec Blog
Follow Us
RSS
Bookstore
Monthly Archives: September 2011
Bringing Genetic Data into the Clinic
While Big Pharma frets over the costs and risks associated with exploratory endpoints in the clinic and the vagaries of companion diagnostic reimbursement, non-profit organizations like the Multiple Myeloma Research Foundation (MMRF) are stepping in to provide pharmacogenomic research for the next generation of cancer drugs.
Posted in Gene therapy, R&D, Regulatory, Strategy, Technology, leadership Tagged clinical research, genetics, pharmacogenomics Leave a comment
Value Isn't Just Dollars and Cents, says Pfizer Exec
Now that 90% of the top 43 countries for drug sales have instituted “significant” cost containment measures, it’s more important than ever to give payers the rest of the story, according to a Pfizer executive.
Posted in Europe, Global, Market Access, Marketing, Patient Communication, Strategy, healthcare, pricing Tagged reimbursement Leave a comment
Deals Don't Need Science To Be A Success
Deals don’t need science to be a success
By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC
Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will best be [...]
Posted in Global, Guest Blog, Strategy Tagged Deals, Genentech, integration, mergers. M&A, Pfizer 2 Comments
Roche Gets Tough on Greece
Roche Gets Tough on Greece, Other Eurozone Countries May Follow
On Friday Roche confirmed it had come to the end of its tether with state-funded hospitals in Greece. In an interview with the Wall Street Journal, CEO Severin Schwan announced that the company has increased shipments of drugs to pharmacies in the country, while cutting off [...]
Posted in Global, healthcare Tagged economic crisis, EU, Europe, eurozone, hospitals, Roche Leave a comment
Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday